Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
Clinical trial NCT01328249 · COMPLETED
Trial details
- NCT number
- NCT01328249
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-03
- Primary completion
- 2014-10-27
- Enrollment
- 81
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.